To include your compound in the COVID-19 Resource Center, submit it here.

Cellectis, Servier, Pfizer report Phase I data for CAR T therapy in adult B-ALL

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), Servier (Neuilly-sur-Seine, France) and Pfizer Inc. (NYSE:PFE) reported preliminary data from seven evaluable adult patients with relapsed or refractory

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE